Illumina Files New Patent Infringement Suit Against Ariosa Diagnostics, Inc.

SAN DIEGO--()--Illumina (NASDAQ:ILMN) announced today that the company has filed a new patent infringement suit against Ariosa Diagnostics, Inc. Illumina is seeking all available remedies, including injunctive relief.

The new suit, filed in the U.S. District Court for the Northern District of California, is based on Ariosa’s infringement of U.S. Patent No. 7,955,794, entitled “Multiplex Nucleic Acid Reactions.” The suit targets Ariosa’s Harmony™ Prenatal Test, including its use of digital analysis of selected regions (DANSR) that, among other things, enables simultaneous quantification of hundreds of DNA loci.

Verinata Health, now a wholly owned subsidiary of Illumina, previously sued Ariosa for infringement of U.S. Patent No. 8,296,076 and U.S. Patent No. 8,318,430 in the U.S. District Court for the Northern District of California. The Court in that case issued a Claim Construction Order providing the Court’s interpretation of the disputed patent terms which supports the position that Ariosa infringes those patents.

Illumina offers the verifi® non-invasive prenatal test (formerly offered by Verinata Health) in its CLIA-certified, CAP-accredited clinical services laboratory, to detect chromosome abnormalities and aberrations with improved resolution for consistent and dependable results. verifi® is the broadest non-invasive prenatal test available today and is part of Illumina’s comprehensive reproductive and genetic health portfolio.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statement for Illumina

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Contacts

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com

Sharing

Contacts

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com